JSPR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Jasper Therapeutics Inc (JSPR) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock shows weak financial performance, limited positive catalysts, and no strong trading signals. While hedge funds are buying, the stock's technicals and lack of recent news or significant analyst upgrades suggest holding off for now.
The MACD is positive and expanding, indicating a potential upward momentum. However, RSI is neutral at 58.218, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below key resistance levels (R1: 1.038) and has weak support at 0.852. Overall, the technicals do not strongly support a buy.
Hedge funds are significantly increasing their positions, with a 364.54% increase in buying over the last quarter.
The company has weak financial performance with declining net income (-62.58% YoY) and EPS (-80.25% YoY). Analysts have lowered price targets, and there is no recent news or significant insider activity to drive the stock upward.
In Q4 2025, revenue remained at 0 with no growth, net income dropped to -$9.1M (-62.58% YoY), and EPS fell to -0.32 (-80.25% YoY). The company shows no signs of financial improvement.
Evercore ISI lowered the price target to $7 from $12 while maintaining an Outperform rating, citing longer-term catalysts. UBS initiated coverage with a Neutral rating and a $1.50 price target, highlighting balanced risk-reward but competitive uncertainties.
